Ruffer LLP’s Teva Pharmaceuticals TEVA Stock Holding History

Ruffer LLP’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q4	–	Sell	-80,000	Closed	-$3.05M	–	99
2013 Q3	$3.05M	Buy	+80,000	New	+$3.12M	0.14%	31

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ruffer LLP's TEVA Position: Q4 2013 in Review

Ruffer LLP sold out of Teva Pharmaceuticals (TEVA) in Q4 2013, closing a stake of 80,000 shares — an estimated $3.05M sold.

Ruffer LLP first reported a position in TEVA in Q3 2013 and held it in 1 quarter. The position peaked at $3.05M in Q3 2013. 727 funds tracked by Wall St. Rank hold TEVA as of Q4 2013.

Ruffer LLP reported no remaining Teva Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
Ruffer LLP sold 80,000 Teva Pharmaceuticals shares in Q4 2013, an estimated $3.05M.
Ruffer LLP first reported a position in Teva Pharmaceuticals in Q3 2013 and held it in 1 quarter.
Ruffer LLP's Teva Pharmaceuticals position peaked at $3.05M in Q3 2013.
727 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2013.

Based on Ruffer LLP's 13F filing for Q4 2013, filed 13 Feb 2014.